BioSpace News Archive

LianBio (Nasdaq: LIAN) today announced the presentation of efficacy and safety data from a Phase 2a study evaluating infigratinib in Chinese patients with locally advanced or metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) with fibroblast growth factor receptor-2 (FGFR2) gene amplification.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced its financial results for the third quarter and nine months ended September 30, 2023, and provided an update on its clinical pipeline and other corporate developments.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

NLS Pharmaceutics Ltd. announced that it has received a written notice from Nasdaq Stock Market LLC indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed companies to maintain a minimum bid price of $1.00 per share.

BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data on the investigational subcutaneous formulation of LEQEMBI showing that it clears 14% more amyloid plaques as measured by PET compared to intravenous infusion (IV), with pharmacokinetics (AUC) 11% higher and similar ARIA rates.

Edwards Lifesciences reported financial results for the quarter ended Sept. 30, 2023.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.

KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”) today announced that the Company will report third quarter 2023 financial results on Wednesday, November 8, 2023.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2023 financial results after the market closes on Wednesday, November 1, 2023.

OPKO Health, Inc. will present late-breaking clinical data on RAYALDEE® extended-release calcifediol at the American Society of Nephrology Kidney Week in Philadelphia on Thursday, November 2, 2023.